This issue of Surgical Oncology Clinics of North America is devoted to the treatment of Colorectal Cancer. Editors Nancy Baxter, MD and Marcus Burnstein, MD have assembled some of the top experts in the field to review this important topic.Articles in this issue include: Colonoscopy: What are we missing?; Imaging in rectal cancer: MRI vs. ERUS; Local Excision for Rectal Cancer; Controversies in Neo-adjuvant treatment for rectal cancer; Management of the complete response; Controversies in laparoscopy for CRC; Colon resection - is standard technique adequate?; Quality Assurance in CRC surgery; Controversies in Abdomino-perineal resection; Functional Consequences of CRC management; Timing of adjuvant therapy for CRC; and Management of Stage IV disease.

2015 BMA Medical Book Awards Highly Commended in Oncology Category! The Molecular Basis of Cancer arms you with the latest knowledge and cutting-edge advances in the battle against cancer. This thoroughly revised, comprehensive oncology reference explores the scientific basis for our current understanding of malignant transformation and the pathogenesis and treatment of this disease. A team of leading experts thoroughly explains the molecular biologic principles that underlie the diagnostic tests and therapeutic interventions now being used in clinical trials and practice. Detailed descriptions of topics from molecular abnormalities in common cancers to new approaches for cancer therapy equip you to understand and apply the complexities of ongoing research in everyday clinical application. Effectively determine the course of malignancy and design appropriate treatment protocols by understanding the scientific underpinnings of cancer. Visually grasp and retain difficult concepts easily thanks to a user-friendly format with abundant full-color figures. Find critical information quickly with chapters following a logical sequence that moves from pathogenesis to therapy. Stay current with the latest discoveries in molecular and genomic research. Sweeping revisions throughout include eight brand-new chapters on: Tumor Suppressor Genes; Inflammation and Cancer; Cancer Systems Biology: The Future; Biomarkers Assessing Risk of Cancer; Understanding and Using Information About Cancer Genomes; The Technology of Analyzing Nucleic Acids in Cancer; Molecular Abnormalities in Kidney Cancer; and Molecular Pathology. Access the entire text and illustrations online, fully searchable, at Expert Consult.

PSA screening remains highly controversial due to several important disadvantages. More PSA is produced with prostatic enlargement and in other benign conditions such as urinary tract infections. False positive tests can then lead to unnecessary diagnostic workup with invasive prostate biopsy. Another major problem with screening programs in general is overdiagnosis of cancers that would not have caused harm during the patient's lifetime. For example, many prostate cancers have a relatively indolent behavior so may not require diagnosis or treatment in a patient with limited life expectancy. All forms of prostate cancer treatment have potential urinary and sexual side effects, so reducing overdiagnosis and overtreatment are critical public health issues. Because screening has many proven benefits but also significant harms, there are widely disparate guidelines on prostate cancer screening from major organizations worldwide. This issue of the Urologic Clinics will provide insights into the many different prostate cancer guidelines and related policy issues.

Bone Cancer, Second Edition comprehensively investigates key discoveries in the field of bone biology over the last five years that have led to the development of entirely new areas for investigation, such as therapies which combine surgery and biological approaches. The Second Edition expands on the original overview of bone cancer development (physiology and pathophysiology), with key chapters from the first edition, and offers numerous new chapters describing the new concepts of bone cancer biology and therapy, for both primary bone tumors as well as bone metastases. Each chapter has been written by internationally recognized specialists on the bone cancer microenvironment, bone metastases, osteoclast biology in bone cancer, proteomics, bone niche, circulating tumor cells, and clinical trials. Given the global prevalence of breast and prostate cancers, knowledge of bone biology has become essential for everyone within the medical and cancer research communities. Bone Cancer continues to offer the only translational reference to cover all aspects of primary bone cancer and bone metastases - from bench to bedside: development (cellular and molecular mechanisms), genomic and proteomic analyses, clinical analyses (histopathology, imaging, pain monitoring), as well as new therapeutic approaches and clinical trials for primary bone tumors and bone metastases.

This issue of Thoracic Surgery Clinics devoted to Therapy for Esophageal Cancer will be Guest Edited by Dr. Wayne Hofstetter. Articles in this issue include: Radiographic and Endoscopic staging of esophageal cancer; Endoscopic management of HGD/Early stage esophageal cancer; Induction chemotherapy for esophageal cancer; Personalizing therapy for esophageal cancer patients; Surgery for esophageal cancer: Goals of resection and optimizing outcomes (Lymph node dissection in esophageal cancer/R0 Resection); Standardizing Esophagectomy Complications; Adjuvant therapy (post-op) for esophageal cancer; Definitive CXRT for esophageal cancer; Salvage Esophagectomy in the management of recurrent or persistent esophageal cancer; and Quality of life after curative resection for esophageal cancer.

Molecular pathology is based on the emergence of new techniques that greatly enhance the diagnostic accuracy when facing with challenging differential diagnoses. In addition, new molecular techniques are entering the clinical arena for their value in predicting therapy response and tumor prognosis. This book provides a guide for the practicing pathologist and for both pathology residents and fellows during the daily sign-out of challenging cases. The book is organized by anatomical systems and provides a detailed description of molecular tests that may help in the diagnosis. Furthermore, a description of the current molecular tests required to identify patients for treatment is offered. The application of molecular pathology techniques to the clinical practice has already shown its usefulness and the number of such tests is growing exponentially as more molecular targets are discovered. Molecular Pathology and Diagnostics of Cancer will give practicing and training pathologists an up-to date resource to guide the correct management of pathology cases requiring molecular testing.

"Advances in Cancer Research" provides invaluable information on the exciting and fast-moving field of cancer research. Here, once again, outstanding and original reviews are presented on a variety of topics Volume 122 explores subjects related to redox, including: redox homeostasis in epithelial-derived cancers; reactive oxygen species in normal and tumor stem cells; and gamma-glutamyl transpeptidase and redox regulation.
Provides information on cancer researchOutstanding and original reviewsSuitable for researchers and students"

This issue focuses on Sarcoma in areas such as: Gastrointestinal Stromal Tumors: Risk assessment and adjuvant therapy, Gastrointestinal Stromal Tumors: Management of metastatic disease and emerging therapies, Liposarcoma, Leiomyosarcoma, Update in treatment and targets in cartilage and bone tumors, Update in treatment and targets in Ewing sarcoma, Angiosarcoma and Epithelioid Hemangioendothelioma, Emerging therapies for sarcoma, and Treatment of localized sarcomas.

This issue of Hematology/Oncology Clinics is focused on Hodgkin's Lymphoma and covers such topics as First HRS-cell line L428 and the detection of the CD-30 Antigen , "Normal" CD30-B-lymphocytes, CD-30-Antigen, Combination-Chemo-Radiotherapy, Early intensification (escBEACOPP), Customized/Targeted Therapy, and more.

"Advances in Cancer Research" provides invaluable information on the exciting and fast-moving field of cancer research. Here, once again, outstanding and original reviews are presented on a variety of topics. This volume covers AEG-1/MTDH/Lyric implicated in multiple human cancers.
Provides information on cancer researchOutstanding and original reviewsSuitable for researchers and students

While cancers of the oral cavity and oropharynx were overwhelming found in smokers and drinkers, a dramatic shift is occurring with a dramatic rise in the incidence of HPV-associated oropharyngeal cancers while oral cavity cancers and HPV-negative oropharyngeal cancers appear to be declining in incidence, reflecting the reduction in cigarette smoking. These trends also have implications for how Otolaryngologists prevent, diagnose, workup, treat, and follow these patients. The focus of information in this issue is on oral cavity and oropharyngeal cancer and the implications of the HPV epidemic on this disease. Amongst the medical community during this period of trying to better grasp the association of HPV with oropharyngeal cancers, there are misconceptions and a lack of knowledge of these important shifts which are addressed by Guest Editors Jeffrey Myers and Erich Sturgis of the University of Texas, MD Anderson Cancer Center. Topics include: Epidemiology- Control of a tobacco epidemic? But emergence of a HPV epidemic?; Oral cavity and Oropharyngeal Cancer Genomics; Why Otolaryngologists need to be aware of Fanconi anemia; Impact on HPV on Orpharyngeal Cancer Biology and Response to Therapy-Implications for Treatment; Oral premalignancy- The roles of early detection and chemoprevention; Evaluation and staging- Limitations despite technological breakthroughs; 7) Surgical treatment innovations; Radiotherapy- The "Particle-rs? of energy, dose, and delivery method; Systemic Treatment- Its role before, during, and after definitive treatment; How to maximize functional assessment/rehabilitation; Standardizing treatment for Cancers - An approach to cancer care or crisis?; Survivorship in Oral Cancer- Competing mortalities, morbidities, and second malignancies.

Cell Press Reviews: Stem Cells to Model and Treat Disease informs, inspires, and connects stem cell researchers and clinicians at all stages in their careers with timely, comprehensive reviews written by leaders in the field and curated by Cell Press editors. The publication offers a broad view of some of the most compelling topics in stem cell research including: Safety and efficacy of stem cell treatmentsStem-cell-based organ regenerationIntegrating stem cells into personalized drug discoveryUsing pluripotent stem cells for treating neurological diseaseEngineering hematopoietic stem cells for innovative therapies

Contributions come from leading voices in the field, including: - Shinya Yamanaka, Recipient of the 2012 Nobel Prize for Physiology or Medicine, Recipient of the 2012 Millennium Technology Prize, Professor and Director of the Center for iPS Cell Research and Application at Kyoto University, Senior Investigator at the Gladstone Institute of Cardiovascular Disease, L.K. Whittier Foundation Investigator in Stem Cell Biology and Professor at the University of California, San Francisco - George Q. Daley, Samuel E. Lux IV Professor of Hematology/Oncology at Harvard Medical School and Director for the Stem Cell Transplantation Program at Boston Children s Hospital - Irving Weissman, Member of National Academy of Sciences, Virgina & D.K Ludwig Professor for Clinical Investigation in Cancer Research, and Director for Institute of Stem Cell Biology and Regenerative Medicine at Stanford University of Medicine

Cell Press Reviews: Stem Cells to Model and Treat Disease is part of the Cell Press Reviewsseries, which features reviews published in "Cell Press" primary research and "Trends" reviews journals.
Provides timely overviews on a wide range of stem cell applications
Offers insight from experts on the key opportunities and challenges facing the field
Features reviews on genetic, cellular, and molecular aspects of stem-cell-based applications
Includes articles originally published in "Cell, Cell Stem Cell, Neuron, Trends in Molecular Medicine," and "Trends in Biotechnology
""

"Advances in Cancer Research" provides invaluable information on the exciting and fast-moving field of cancer research. Here, once again, outstanding and original reviews are presented on a variety of topics.
Provides information on cancer researchOutstanding and original reviewsSuitable for researchers and students

Recent evidence demonstrates that normal prostate tissue contains stem cells. There is also accumulating evidence that prostate cancer contains a population of cells with stem cell-like characteristics referred to as cancer stem cells, or tumor initiating cells. Both the normal prostate stem cell and cancer stem cell populations have important implications for the generation, therapeutic targeting, and prevention of prostate cancer. The purpose of this book is to explore the role of stem cells in prostate cancer, which is becoming an increasingly hot trend in cancer research.

Lynch syndrome (LS) is the most common cause of inherited colorectal cancer, a disease with a high mortality rate. An estimated 37,000 of diagnosed colorectal cancer cases worldwide are attributed to Lynch syndrome each year. Intensive cancer screening, with early initiation and frequent follow-up, can reduce colorectal cancer incidence and mortality in LS patients. This book provides an up-to-date overview on the genetic and epigenetic basis of Lynch syndrome. It evaluates clinical features of the disease and critically comments on molecular tools available for identifying mutations responsible for Lynch syndrome; in addition the importance of functional assays that can help clarify the clinical nature of identified mutations is also discussed. The book also focuses on challenges in genetic counselling of at-risk individuals and discusses related ethical issues. The purpose of the book is to give a concise knowledge base for the broader scientific and medical community, including genetic counselors, in order to improve awareness on the potential impact that the diagnosis of LS has on treatment, management and surveillance of LS patients.

Volume 542 of "Methods in Enzymology" continues the legacy of this premier serial with quality chapters authored by leaders in the field. This new volume covers research methods providing a theoretical overview on metabolic alterations of cancer cells and a series of protocols that can be employed to study oncometabolism, in vitro, ex vivo and in vivo. Malignant cells exhibit metabolic changes when compared to their normal counterparts, owing to both genetic and epigenetic alterations. Although such a metabolic rewiring has recently been indicated as "yet another" general hallmark of cancer, accumulating evidence suggests that the metabolic alterations of each neoplasm rather represent a molecular signature that intimately accompanies, and hence cannot be severed from, all facets of malignant transformation.
Continues the legacy of this premier serial with quality chapters authored by leaders in the field Covers research methods in biomineralization scienceProvides theoretical overview on metabolic alterations of cancer cells, and a series of protocols that can be employed to study oncometabolism, in vitro, ex vivo and in vivo

Complementary & Alternative Medicine (CAM) for Prostate/Urologic Health is designed to capture and clinically review the comprehensive database of clinical research articles that support and do not support the utilization of a variety of dietary supplements and other complementary medicines that physicians are exposed to in their daily practice. This is a critical distinction between this book and any other CAM Complementary & Alternative Medicine for Prostate and Urologic Health is designed to capture and clinically review the comprehensive database of clinical research articles that support and do not support the utilization of a variety of dietary supplements and other complementary medicines that physicians are exposed to in their daily practice. This is a critical distinction between this book and any other Complementary & Alternative Medicine (CAM) books published to date. Each section of the book provides an easy to reference guide into the topic of interest for the individual that works in urology. The various sub-specialty groups in urology are adequately represented, which allows for a physician to rapidly and thoroughly investigate their topic of interest regardless of whether it is fertility, bladder cancer, or prostate disease. Rather than having to sort through the now thousands of articles published yearly on CAM in medicine, this volume focuses first on the specialty and secondarily how it compares to the overall CAM literature. Each chapter includes a summary page that will allow the physician a rapid review of the subject with a patient, colleague or student. The practical nature of this book in urology also cannot be overstated. Chapters include a general overview of the CAM agent, whether or not it has data in medicine and urology, and a list of potential drug interactions and specific clinical scenarios where it can be utilized or discouraged in the specialty. Complementary & Alternative Medicine for Prostate and Urologic Health represents a gold standard text for use in teaching, not only for the students interested in the urologic field but for all current urologic health providers.

Gene therapy as a treatment for cancer is at a critical point in its evolution. Exciting new developments in gene targeting and vector technology, coupled with results from the first generation of preclinical and clinical studies have led to the design and testing of new therapeutic approaches. The Third Edition of "Gene Therapy of Cancer" provides crucial updates on the basic and applied sciences of gene therapy. It offers a comprehensive assessment of the field including the areas of suicide gene therapy, oncogene and suppressor gene targeting, immunotherapy, drug resistance gene therapy, and the genetic modification of stem cells. Researchers at all levels of development, from basic laboratory investigators to clinical practitioners, will find this book to be instructive.

Cancer gene therapy, like cancer therapy in general, is evolving rapidly, testing new concepts, targets and pathways, evoking new technologies, and passing new regulatory hurdles. Its essence, however, has not changed: the hope and challenges of returning altered genes to normal, using targeted gene expression to alter the function of both tumor and microenvironment, and in some cases normal cells, and delivering functionally important genes to specific cell types to increase sensitivity to killing or to protect normal cells from cancer therapies.

In some instances, gene therapy for cancer forms a continuum from gene repair through the use of molecularly modified cells; the use of viral and non-viral vector based gene delivery to both tumor and tumor microenvironment; the use of viral and gene based vaccines; and development of new gene-based therapeutics. The unique mechanistically chosen vector platforms are at the heart of this technology because they allow for direct and selective cell death and transient to sustained delivery of vaccine molecules or molecules that affect the microenvironment, vasculature, or the immune response.
Explains the underlying cancer biology necessary for understanding proposed therapeutic approaches Presents in-depth description of targeting systems and treatment strategiesCovers the breadth of gene therapy approaches including immunotherapeutic, drug resistance, oncolytic viruses, as well as regulatory perspectives from both the NCI and FDA

This unique book provides a retrospective analysis of the changes in survival outcomes at the University of Texas, M.D. Anderson Cancer Center over the past six decades. Since opening its doors in 1944, M.D. Anderson has kept a continuous, uninterrupted data repository of the treatment and outcomes of each of its patients. It is this visionary database from the center s tumor registry which makes this groundbreaking book possible. Tracking results across time, this book shows radical shifts in outcomes trends, where great progress has been made, and where there is still a long way to go, and offers a snapshot into the parallel history of developments in care. Such data is crucial to informing how patients are counseled, how treatment decisions are determined, and how prognoses are made.

"60 Years of Survival Outcomes at the University of Texas, M.D. Anderson Cancer Center" is the only book to concurrently present longitudinal data on survival outcomes across the spectrum of rare and common cancers. Each chapter deals with a specific disease site, discussing current management approaches and presenting key data replete with illustrative charts, graphs, and tables. With the resources available only to the practitioners at this inimitable institution, this book heralds a cornerstone moment in the study of survival outcomes and the depth of our knowledge of cancer care. "

"Molecular Diagnostics andTreatment of Pancreatic Cancer "describes the different emerging applications of systems biology and howit is shaping modern pancreatic cancer research. This book begins by introducing the current state of the art knowledge, trends in diagnostics, progress in disease model systems as well as new treatment and palliative care strategies in pancreatic cancer. Specific sections are dedicated to enlighten the readers to newer discoveries that have emerged from gene expression profiling, proteomics, metabolomics and systems level analyses of pancreatic cancer datasets. First of a kind and novel network strategies to understand oncogenic Kras signaling in pancreatic tumors are presented. The attempts to computationally model and prioritize microRNAs that cause pancreatic cancer resistance are alsohighlighted.

Addressing this important area, "Molecular Diagnostics and Treatment of Pancreatic Cancer" provides insights into important network evaluation methodologies related to pancreatic cancer related microRNAs targetome. There are dedicated chapters on critical aspects of the evolving yet controversial field of pancreatic cancer stems cells. The work concludes by discussing the applications of network sciences in pancreatic cancer drug discovery and clinical trial design.
Encompasses discussion of innovative tools including expression signatures in cell lines, 3D models, animal xenograft models, primary models and patient derived samples, aiding subversion of traditional biology paradigms, and enhancing comprehension across conventional length and temporal scalesCoverage includes novel applications in targeted drugs, polypharmacology, network pharmacology and other related drug development arenas - helping researchers in pancreatic cancer drug discoverySummarizes many relevant computational and clinical references from fast-evolving literatureComprehensive glossary helps newer readers understand technical terms and specialized nomenclature"

Extensive research into the molecular mechanisms of cancer has heralded a new age of targeted therapy. The field of personalized cancer therapy is now growing rapidly, and the progress being made will result in significant changes in the treatment algorithms for cancer patients. Numerous novel targets that are crucial for the survival of cancer cells can be attacked by small molecules such as protein tyrosine kinase inhibitors. This book, written by acknowledged experts, discusses in detail the most recent developments in targeted cancer therapy using small molecules. A wide range of small molecules is covered, including, in addition to tyrosine kinase inhibitors, mTOR, proteasome, and multikinase inhibitors, among others. For each molecule, aspects such as chemical structure, mechanism of action, drug targets, drug interactions, preclinical studies, clinical trials, treatment applications, and toxicity are discussed.

Aiding researchers seeking to eliminate multi-step procedures, reduce delays in treatment and ease patient care, "Cancer Theranostics" reviews, assesses, and makes pertinent clinical recommendations on the integration of comprehensive in vitro diagnostics, in vivo molecular imaging, and individualized treatments towards the personalization of cancer treatment.

"Cancer Theranostics" describes the identification of novel biomarkers to advance molecular diagnostics of cancer. The book encompasses new molecular imaging probes and techniques for early detection of cancer, and describes molecular imaging-guided cancer therapy. Discussion also includes nanoplatforms incorporating both cancer imaging and therapeutic components, as well as clinical translation and future perspectives.
Supports elimination of multi-step approaches and reduces delays in treatments through combinatorial diagnosis and therapyFully assesses cancer theranostics across the emergent field, with discussion of biomarkers, molecular imaging, imaging guided therapy, nanotechnology, and personalized medicine Content bridges laboratory, clinic, and biotechnology industries to advance biomedical science and improve patient management